CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Inclusion Criteria: * Greater than four years of age * Survival time\>12 weeks * B cell hematological malignancies by pathological examination * Chemotherapy failure or recurrent B cell malignancy * Creatinine\< 2.5mg/dl * Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase\< 3 fold of normal level * Bilirubin\<2.0mg/dl * Karnofsky Performance Status\>50% at the time of screening * Adequate pulmonary, renal, hepatic, and cardiac function * Fail in autologous or allogenic haemopoietic stem cell transplantation * Free of leukocytes removal contraindications * Voluntarily join CAR-T clinical trial * Understand and sign written informed consent Exclusion Criteria: * Pregnant or nursing women * Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening * Feasibility assessment proves that the efficiency of transduction of lymphocyte is below 10% or the lymphocyte cannot be propagated. * Abnormal vital signs * Highly allergic constitution or history of severe allergies, especially allergy to interleukin-2 * General infection or local severe infection, or other infection that is not controlled * Dysfunction in lung, heart, kidney and brain * Severe autoimmune diseases * Other symptoms that are not applicable for CAR-T